189 related articles for article (PubMed ID: 28477178)
1. Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.
Luvero D; Plotti F; Lopez S; Scaletta G; Capriglione S; Montera R; Antonelli G; Ciuffreda S; Carassiti R; Oliveti A; Angioli R
Med Oncol; 2017 Jun; 34(6):115. PubMed ID: 28477178
[TBL] [Abstract][Full Text] [Related]
2. From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?
Luvero D; Lopez S; Bogani G; Raspagliesi F; Angioli R
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33050484
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and targeted therapy for cervical cancer: an update.
Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
[TBL] [Abstract][Full Text] [Related]
4. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G; Manzano A; Casado A
Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs for the treatment of cervical cancer.
Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors in the management of breast cancer.
Bossung V; Harbeck N
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):79-86. PubMed ID: 19952746
[TBL] [Abstract][Full Text] [Related]
7. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Crafton SM; Salani R
Clin Ther; 2016 Mar; 38(3):449-58. PubMed ID: 26926322
[TBL] [Abstract][Full Text] [Related]
8. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
García-Martínez E; Redondo A; Piulats JM; Rodríguez A; Casado A
Angiogenesis; 2020 Nov; 23(4):543-557. PubMed ID: 32691290
[TBL] [Abstract][Full Text] [Related]
9. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
10. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
Dizon DS
Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine.
Trifanescu OG; Anghel R
Maedica (Bucur); 2015 Sep; 10(4):376-381. PubMed ID: 28465743
[TBL] [Abstract][Full Text] [Related]
12. Update on novel therapeutic agents for cervical cancer.
del Campo JM; Prat A; Gil-Moreno A; Pérez J; Parera M
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S72-6. PubMed ID: 18544460
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.
Longoria TC; Tewari KS
Drugs; 2015 Nov; 75(16):1853-65. PubMed ID: 26474780
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
17. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
Tewari KS; Monk BJ
Clin Cancer Res; 2014 Nov; 20(21):5349-58. PubMed ID: 25104084
[TBL] [Abstract][Full Text] [Related]
18. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
Schmid BC; Oehler MK
Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
[TBL] [Abstract][Full Text] [Related]
19. Emerging antiangiogenics for renal cancer.
Domblides C; Gross-Goupil M; Quivy A; Ravaud A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):495-511. PubMed ID: 24274612
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D; Temraz S; Wehbe D; Shamseddine A
Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
